Bioheart-B (02185.HK) surged more than 28% during late trading, rising 25.71% to HK$4.84 by market close with turnover reaching HK$27.26 million. The rally follows the U.S. Centers for Medicare & Medicaid Services (CMS) releasing a new proposal recommending Medicare coverage for Renal Denervation (RDN) therapy in patients with uncontrolled hypertension. This proposal has entered a 30-day public comment period, with a final decision expected by October 8, 2025.

Industry analysts suggest this policy shift could accelerate RDN adoption, potentially creating growth opportunities for medical device companies including Medtronic. Notably, Bioheart's Shanghai-based subsidiary Antong Medical completed the first commercial surgery using its Iberis multi-electrode renal artery radiofrequency ablation system in Germany last February. On June 3, the company announced the Iberis RDN system's official launch during the 19th Oriental Congress of Cardiology on May 31. The Iberis system remains the world's only RDN product simultaneously compatible with both transradial and transfemoral access routes.